How much funding has Secretome Therapeutics raised?

Secretome Therapeutics has raised $52.4M in total funding, most recently a Series A round.

Who are Secretome Therapeutics's investors?

Secretome Therapeutics's investors include Unknown, RA Capital Management.

When was Secretome Therapeutics founded?

Secretome Therapeutics was founded in 2018.

Where is Secretome Therapeutics headquartered?

Secretome Therapeutics is headquartered in Baltimore, Maryland, United States.

What industry is Secretome Therapeutics in?

Secretome Therapeutics operates in Biotech.

How many employees does Secretome Therapeutics have?

Secretome Therapeutics has 1-10 employees.

Secretome Therapeutics

A New Standard in Regenerative Medicine.

Baltimore, United States · Founded 2018 · $52.4M raised

Biotech

Headquarters: Baltimore, Maryland
Employees: 1–10
Founded: 2018
Business Model: B2B

Website: secretometherapeutics.com
Total Funding: $52.4M
Last Round: $30.0M Series AMay 2026
Rounds: 5

About

Secretome Therapeutics (formerly NeoProgen) is a clinical-stage biotechnology company developing novel regenerative medicines derived from neonatal cardiac progenitor cells. Lead candidate STM-01 targets heart failure with preserved ejection fraction, dilated cardiomyopathy, and Duchenne-associated cardiomyopathy.

Summary

Secretome Therapeutics is a Biotech company based in Baltimore, United States, founded in 2018. It has raised $52.4M in total across 5 rounds, most recently a $30.0M Series A round in May 2026. Investors include Unknown and RA Capital Management.

LinkedIn X (Twitter)